Pur­due's mul­ti-bil­lion dol­lar set­tle­ment in jeop­ardy af­ter fed­er­al judge toss­es deal; Bio­Marin an­nounces glob­al gene ther­a­py col­lab­o­ra­tion

Well, Pur­due Phar­ma’s mul­ti-bil­lion dol­lar opi­oid set­tle­ment is now in jeop­ardy — a fed­er­al judge just said no.

Colleen McMa­hon, a judge on the US Dis­trict Court for the South­ern Dis­trict of New York, said that the set­tle­ment, which would dis­solve Pur­due Phar­ma and was ap­proved in Sep­tem­ber by a bank­rupt­cy judge, should not go for­ward be­cause it re­leas­es the com­pa­ny’s own­ers, mem­bers of the bil­lion­aire Sack­ler fam­i­ly, from li­a­bil­i­ty in civ­il opi­oid-re­lat­ed cas­es.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER